drugset / Trial / NCT06631989

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

NCT06631989

Phase 1/2 Recruiting 100 enrolled Wayshine Biopharm, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .

Timeline

Start
2024-09-04
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject WSD0922-FU Unknown Oral

Indications